Effect of ursodeoxycholic acid administration in patients with primary hypercholesterolaemia

Clinical Drug Investigation

Volumn 18, Issue 4, 1999, Pages 263-269

  Cicognani, Camilla ^a   Malavolti, Mauro ^a   Morselli Labate, Antonio Maria ^a   Talarico, Raffaella ^a   Zamboni, Luisella ^a   Sama, Claudia ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; URSODEOXYCHOLIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032756930     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199918040-00002     Document Type: Article

References (38)

1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 Years of follow-up from the Framingham Study. JAMA 1987; 257: 2176-80
2. Fromm H. Bile acid-lipoprotein interactions: Effects of ursode-oxycholic acid (ursodiol). Dig Dis Sci 1989; 34: 21S-23S
3. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993; 34: 1637-59
4. Poupon RE, Ouguerram K, Chretien Y, et al. Cholesterollowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 1993; 17: 577-82
5. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis Part II. Dig Dis Sci 1982; 27: 833-56
6. Einarsson K. Effect of ursodeoxycholic acid on hepatic cholesterol metabolism. Scand J Gastroenterol 1994; 29 Suppl. 204: 19-23
7. Tint GS, Salen G, Shefer S. Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism. Gastroenterology 1986; 91: 1007-18
8. Malavolti M, Fromm H, Ceryak S, et al. Modulation of low density lipoprotein receptor activity by bile acids: Differential effects of chenodeoxycholic and ursodeoxycholic acids in the hamster. J Lipid Res 1987; 28: 1281-95
9. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Circulation 1994; 89: 1333-445
10. Johnston DE, Hofmann AF, Pathogenesis and treatment of gallstones. N Engl J Med 1993; 328: 412-21
11. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 1994; 29: 1-15
12. Hardison WGM, Grundy SM. Effect of ursodeoxycholate and its taurine conjugate on bile acid synthesis and cholesterol absorption. Gastroenterology 1984; 87: 130-5
13. Malavolti M, Ceryak S. Fromm H. Increased low density lipoprotein (LDD) clearance after feeding of ursodeoxycholic acid (UDCA) in the hamster. Gastroenterology 1991; 100: A703
14. European Atherosclerosis Society Study Group. Strategies for the prevention of coronany heart disease: A policy statement of the European Atherosclerosis Society. Eur Heart J 1987 Jan; 8 (1): 77-88
15. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-14
16. Röschlau P, Bernet E, Gruber W, et al. Cholesterol and esterified cholesterol. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. 2nd English Edition. New York, San Francisco, London: Academic Press, 1974; Vol. 4: 1890-3
17. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
18. Bachorik PS, Lovejoy KL, Carroll MD, et al. Measurement of apolipoprotein A-I and B during the national health and nutrition examination survey (NHANES) III. Clin Chem 1994; 40; 1915-20
19. Denke MA, Sempos CT, Grundy SM. Excess body weight. An under-recognized contributor to high blood cholesterol levels in while American men. Arch Intern Med 1993; 153: 1093-103
20. Denke MA, Sempos CT, Grundy SM. Excess body weight. An under-recognized contributor to dyslipidemia in white American women. Arch Intern Med 1994; 154: 401-10
21. Norusis MJ, and SPSS Inc. SPSS/PC+ 4.0 Base and Advanced Statistics Manuals. SPSS Inc., Chicago (IL) 1990
22. Qureshi AA, Bradlow BA, Brace L. et al. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids 1995; 30: 1171-7
23. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995; 18: 393-7
24. Chan EK, Schroeder DJ. Psyllium in hypercholesterolemia. Ann Pharmacother 1995; 29: 625-7
25. Korhonen T, Savolainen MJ, Jaaskelainen T, et al. Effect of a synthetic prostaglandin E2 analogue, RS-86505-007, on plasma lipids and lipoproteins in patients with moderate hypercholesterolaemia: Efficacy and tolerance of treatment and response in different apolipoprotein polymorphism groups. Eur J Clin Pharmacol 1995; 48: 97-102
26. Gylling H, Vanhanen H, Miettinen TA. Effects of ketoconazole on cholesterol precursors and low density lipoproteins kinetics in hypercholesterolemia. J Lipid Res 1993; 34: 59-67
27. Bell L, Halstenson CE, Halstenson CJ, et al. Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. Arch Intern Med 1992; 152: 2441-4
28. Miettinen TA, Puska P, Gylling H, et al. Reduction of serum cholesterol with silostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333: 1308-12
29. Fromm H, Roat JW, Gonzales V, et al. Comparative efficacy and side effects of ursodeoxycholic acid in dissolving gallstones: A double-blind controlled study. Gastroenterology 1983; 85: 1257-64
30. O'Brien CB, Senior JR, Arona-Mirchandani R, et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30-month pilot study. Hepatology 1991; 14: 838-47
31. Podda M, Ghezzi C, Battezzati PM, et al. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990; 98: 1044-50
32. Queneau PE, Berault-Peres P, Guitaoni M, et al. Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat. Dig Dis Sci 1994; 39: 1581-5
33. Cicognani C, Malavolti M, Morselli-Labate AM, et al. Flutamide-induced toxic hepatitis: Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig Dis Sci 1996; 41: 2219-21
34. Jahn CE, Schafer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Gastroenterology 1985; 89: 1266-78
35. Miettinen TA, Farkkila M, Vaoristo M, et al. Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine. Hepatology 1995; 21: 1261-8
36. Marteau P, Chazouilleres O, Myara A, et al. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Gastroenterology 1990; 98: 1206.8
37. Malavolti M, Ceryak S, Fromm H. Modulation of bile secretion by hepatic low-density lipoprotein uptake and by cheno-deoxycholic acid and ursodeoxycholic acid treatment in the hamster. Gastroenterology 1987; 93: 1104-15
38. Bouscarel B, Ceryak S, Robins SJ, et al. Studies of the mechanism of the ursodeoxycholic acid-induced increase in hepatic low-density lipoprotein binding. Lipids 1995; 30: 607-17